Profiles of Leading Women Scientists on AcademiaNet.
Search among the members of the Leopoldina for experts in specific fields or research topics.
Nobel Prize in Chemistry 2004
Year of election: | 2016 |
Section: | Biochemistry and Biophysics |
City: | Haifa |
Country: | Israel |
Research Priorities: proteins, ubiquitin, ubiquitin-directed protein degradation, ubiquitin-proteasome system (UPS), protein degradation disorders
Aaron Ciechanover is a biochemist. He investigates cellular mechanisms that mark proteins for degradation. His discovery that the regulatory protein ubiquitin attaches to a target protein in order to control its degradation process made him world-famous. In 2004, he was awarded the Nobel Prize in Chemistry together with Avram Hershko and Irwin Rose for this discovery. The scientists had thus provided essential insights into disposal of defective or excess proteins from cells. Protein degradation disorders are responsible for various diseases.
The degradation process of defective or unwanted proteins is essential for the cell's survival. If the inactive proteins are not disposed of, they can become harmful. Aaron Ciechanover and his research team have recognised that the degradation of cellular proteins takes place in several steps, is temporally controlled and strictly regulated. The scientists uncovered that this process engages the molecule ubiquitin and that protein degradation is also instrumental in regulating other cellular processes, including cell cycle and division, differentiation, signal transduction, maintaining the integrity of the genome and proteome, and the cell's many communication pathways.
Disturbances in the degradation process can lead to diseases such as cancer, cystic fibrosis, Parkinson's, Alzheimer's and other neurodegenerative and inflammatory diseases. Research into the so-called ubiquitin-proteasome system by Aaron Ciechanover and his colleagues has led to the development of a novel cancer medication. With further research activities, including precision medicine, medications can be developed to target the proteins involved in the disease process specifically.